{'52WeekChange': 0.6273447,
 'SandP52WeekChange': 0.0644362,
 'address1': '820 South Friendswood Drive',
 'address2': 'Suite 201',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 39.14,
 'askSize': 1200,
 'averageDailyVolume10Day': 133862,
 'averageVolume': 234133,
 'averageVolume10days': 133862,
 'beta': None,
 'beta3Year': None,
 'bid': 39,
 'bidSize': 800,
 'bookValue': 4.822,
 'category': None,
 'circulatingSupply': None,
 'city': 'Friendswood',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 40.22,
 'dayLow': 37.705,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': 66.147,
 'enterpriseToRevenue': 9.889,
 'enterpriseValue': 598963072,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 40.069286,
 'fiftyTwoWeekHigh': 45.62,
 'fiftyTwoWeekLow': 15.26,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 11112775,
 'forwardEps': -0.99,
 'forwardPE': -39.434345,
 'fromCurrency': None,
 'fullTimeEmployees': 133,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'heldPercentInsiders': 0.27997,
 'heldPercentInstitutions': 0.52751,
 'industry': 'Diagnostics & Research',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/castlebiosciences.com',
 'longBusinessSummary': 'Castle Biosciences, Inc., a commercial-stage '
                        'dermatological cancer, develops and commercializes '
                        'diagnostic and prognostic tests for cancers. Its lead '
                        'product is DecisionDx-Melanoma, a multi-gene '
                        'expression profile (GEP) test to identify stage I and '
                        'II patients at high risk of metastasis based on '
                        'biological information from 31 genes within their '
                        'tumor tissue. The company also offers DecisionDx-UM '
                        'test, a proprietary GEP test that predicts the risk '
                        'of metastasis for patients with uveal melanoma, a '
                        'rare eye cancer; and two late-stage proprietary '
                        'products in development, which address cutaneous '
                        'squamous cell carcinoma and suspicious pigmented '
                        'lesions, which are indications with high clinical '
                        'need in dermatological cancer. It offers test '
                        'services through physicians, physician assistants, '
                        'and nurse practitioners. The company was founded in '
                        '2007 and is headquartered in Friendswood, Texas.',
 'longName': 'Castle Biosciences, Inc.',
 'market': 'us_market',
 'marketCap': 767530304,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_60295846',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': 5903000,
 'nextFiscalYearEnd': 1640908800,
 'open': 39.5,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '866 788 9007',
 'previousClose': 40.11,
 'priceHint': 2,
 'priceToBook': 8.096226,
 'priceToSalesTrailing12Months': 12.6726265,
 'profitMargins': 0.11896,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 40.22,
 'regularMarketDayLow': 37.705,
 'regularMarketOpen': 39.5,
 'regularMarketPreviousClose': 40.11,
 'regularMarketPrice': 39.5,
 'regularMarketVolume': 119339,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 19660100,
 'sharesPercentSharesOut': 0.0572,
 'sharesShort': 1107848,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 1286964,
 'shortName': 'Castle Biosciences, Inc.',
 'shortPercentOfFloat': 0.099700004,
 'shortRatio': 3.55,
 'startDate': None,
 'state': 'TX',
 'strikePrice': None,
 'symbol': 'CSTL',
 'threeYearAverageReturn': None,
 'toCurrency': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -0.207,
 'twoHundredDayAverage': 33.27252,
 'volume': 119339,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://castlebiosciences.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '77546'}